ADELAIDE, Australia, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Avance Clinical, a full-service biotech-focused global contract research organisation (CRO) headquartered in Australia, will exhibit at Booth ...
The approval includes 40 mg and 50 mg twice-daily dosing for eligible pediatric patients in this weight group, making Joenja the first treatment approved in the U.K. specifically for children with ...
The second annual Global Health Congress (GHC) concluded at the Yale Club of New York City with more than 625 healthcare leaders from 25+ countries, 125+ speakers and representatives from 350+ ...
Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations ...
Reported third quarter 2026 revenue of $212,000 during the transition period from Platinum® to Proteus, which is expected to continue through the first half of 2027 Highlighted interim Proteus ...
MediWound Announces Closing of $17.25 Million Bought Deal Offering of Ordinary Shares ...
In October 2026, the Company provided an update that the U.S. Food and Drug Administration (FDA or the Agency) has reviewed additional study data provided by the Company at the Agency’s request.
AUSTIN, Texas, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI), a medical device company redefining stroke recovery for survivors living with life-altering motor impairments, ...
ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today an ...
Announced follow-on publication in The New England Journal of Medicine (NEJM) highlighting long-term data and durability of hypoimmune-modified islet cell transplantation with UP421 without ...
Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that the Company will report results for the third ...
CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results